2018 American Transplant Congress
Malignancy Complications after Kidney Transplantation, the Role of Immunosuppression
Introduction: Immunosuppression therapy is essential to avoid rejection after kidney transplantation. The chronic use of this drugs increases the risk of malignancy compared to general…2018 American Transplant Congress
Reduction in Circulating CD19+CD24+CD27+ Regulatory B Cell Frequency Predicts Acute Rejection in Liver Transplant Patients
Liver Transplant Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating inflammation and autoimmune diseases. However, whether Bregs regulate acute liver…2018 American Transplant Congress
Single-Dose Pharmacokinetics and Pharmacodynamics of Belatacept in Adolescent Kidney Transplant Recipients
Purpose: To assess the pharmacokinetics (PK) and pharmacodynamic (PD) effect of a single dose of belatacept (bela) administered to adolescent kidney transplant recipients (KTR).Methods: In…2018 American Transplant Congress
Alemtuzumab Induction as a Mediator of Nonadherence in Renal Transplantation
University of Toledo College of Medicine, Toledo, OH.
Introduction: “Non-adherent” (NA) is defined as chronic follow-up absenteeism or medication nonadherence. We aimed to determine whether the single-dosing schedule of Alemtuzumab (Ale) may limit…2018 American Transplant Congress
Impact of Steroid Maintenance on the Outcomes of HLA-DR Mismatch Kidney Transplantation
Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch poses high immunologic risk and is associated with inferior outcomes. We aimed to explore the impact of enhanced immunosuppression…2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…2018 American Transplant Congress
Clinical Outcomes of Late Conversion to Once-Daily Tacrolimus after Liver Transplant
BackgroundSince a once-daily tacrolimus (TAC-OD) has been introduced in the field of transplantation, many studies reported advantages of the new drug, such as the better…2018 American Transplant Congress
Persistence and Homing of Autologous Donor-Reactive Ex-Vivo Expanded Regulatory T Cells to Heart Allografts in Lymphodepleted Recipient Monkeys
Surgery, Starzl Transplantation Institute, Pittsburgh, PA.
Background:Infusion of ex vivo expanded regulatory T cells (Treg) is a promising therapy to prevent allograft rejection. Trafficking of Treg to allografts and secondary (2ry)…2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 138
- Next Page »